In partnership with

Anna's Daybreak News

_{Just facts, you think for yourself}

Thursday, 5:19 AM

November 13, 2025

Good morning news friend! Discover today’s defining stories and the future they set in motion. 📰🌟

Notice: If you’re reading this email in the Gmail app, you will not be able to see both of our health articles at the bottom. 👉 Click here to view the full newsletter online — it’s free and easy to read.

Government Reopens

The U.S. government shutdown ended after 43 days when President Trump signed a spending bill funding operations through January 30, 2026. The House passed it 222-209, with six Democrats joining Republicans; two Republicans opposed.

Federal workers return Thursday with retroactive pay. Services including SNAP food aid resume, though full restoration will take longer. The shutdown cut over 0.1% off GDP weekly and paused key economic data releases. The dispute centered on extending federal health care subsidies, opposed by most Republicans.

The bill includes a controversial provision allowing eight Republican senators to sue over January 6 phone-record seizures. Public opinion is nearly split on shutdown blame, while Congress faces pressure to resolve health care disputes to avoid future shutdowns.

Sources: Bloomberg, AP News, Reuters, NYTimes. 

Epstein Emails

House Democrats released 20,000+ pages of Epstein documents, including emails linking Trump to Virginia Giuffre and suggesting Trump knew about Epstein’s girls. Republicans identified the redacted victim and challenge selective release claims.

A bipartisan House petition, now with 218 signatures, seeks full DOJ Epstein file disclosure, forcing a House vote next week. Four Republicans, including Boebert and Greene, support transparency despite White House pressure to retract.

Trump calls the investigation a distraction. Epstein died by suicide in 2019; Maxwell is serving 20 years for sex trafficking. DOJ has released limited files, and the vote faces likely Senate opposition and a possible Trump veto, continuing political tensions.

Sources: ABC, NYTimes, AP News, Lemonde, CNBC, Pbs.

Court Pauses Order to Break Delta-Aeroméxico Partnership

A U.S. appeals court paused a Trump administration order requiring Delta Air Lines and Aeroméxico to end their nearly nine-year joint venture by January 1, 2026.

The DOT had terminated antitrust immunity and revoked route approvals, citing competition concerns. Delta owns 20% of Aeroméxico, and together they control about 60% of Mexico City flight operations. The court stay delays enforcement while reviewing the case. The administration also canceled combined passenger and cargo flights from Mexico City’s Felipe Angeles Airport.

Mexican President Claudia Sheinbaum opposed the U.S. decision. Both airlines warned of substantial unrecoverable costs if forced to dissolve the alliance before legal resolution.

Sources: Reuters, Globenewswire, Bloomberg, Tradingview.

Did you know we also write in-depth deep dives? They are long, packed with insights, and have received rave reviews. If you’re up for a detailed, action-packed read, check them out:

• Muscle-Centric Medicine

• 2026 tax Sunset

• The Widowhood Penalty

• The Asset Protection Blueprint

• The Retirement Tax Bomb

• Inflammation Crisis

• The Gut Brain Axis

Personalized Gene-Editing Treatments

The FDA introduced a “plausible mechanism” fast-track pathway for personalized gene-editing therapies targeting ultra-rare, fatal genetic diseases. Approvals can be based on small patient studies showing clinical improvement linked to the disease’s biological cause.

Post-approval, companies must collect real-world safety and efficacy data. The pathway emerged from cases like infant KJ Muldoon’s rapid CRISPR treatment for a rare liver disease. Initially for ultra-rare diseases, the program may extend to common diseases without effective treatments and to other therapy types beyond gene editing.

Meanwhile, biotech deals continue amid safety and funding challenges, including Lilly acquiring Verve for $1 billion and Arbor raising $74 million.

Sources: Bloomberg, Statnews, Reuters, Biopharmadive.

Fatty Liver Disease Mutations

Researchers identified a rare MET gene mutation that directly causes metabolic dysfunction-associated steatotic liver disease (MASLD), affecting one-third of adults globally.

This mutation disrupts liver fat metabolism, leading to fat accumulation, inflammation, fibrosis, cirrhosis, and liver cancer. The finding emerged from a family lacking typical MASLD risk factors, where genomic analysis pinpointed a single-letter change in the MET gene.

Among 4,000 MASLD patients in a cohort of 100,000, 1% carried rare MET variants; 18% shared mutations in the noted gene region. This implies millions worldwide might have similar mutations. The discovery enhances genome sequencing’s role in diagnosing MASLD and opens paths to targeted treatments.

Sources: SciTechDaily.

Heart Failure Saliva Test

Researchers developed a saliva test detecting protein S100A7, linked to heart failure, which is nearly twice as high in patients. Using synthetic protein via mRNA display technology, the test binds S100A7 for accurate, fast, and inexpensive detection.

Trials with 31 patients showed 81% agreement with standard assays and 82% accuracy ruling out heart failure in healthy subjects, outperforming current tests at 52%. The small sample size requires larger studies before clinical use.

The test could improve early heart failure diagnosis, especially in remote or low-resource areas, enabling timely treatment. Researchers plan to adapt the method to detect other diseases by targeting different proteins.

Sources: Sciencealert, Newatlas, Medicalxpress.

“A man who makes himself the main topic of his own conversation has only two choices: either he can brag, which is just vanity with its chest puffed out, or he can run himself down, which is a poor-spirited business that makes everybody in the room feel tired. Either way, he is a nuisance, and the folks listening are just waiting for him to finish.”

Baked with love,

Anna Eisenberg ❤️